蛋白質組學：技術和全球市場

全球蛋白質組學市場規模預計將從 2022 年的 271 億美元增長到 2027 年的 551 億美元，2022 年至 2027 年的複合年增長率為 15.3%。

藥物發現和開發行業預計將從 2022 年的 140 億美元增長到 2027 年的 261 億美元，2022 年至 2027 年的複合年增長率為 13.2%。 診斷行業也預計將從 2022 年的 74 億美元增長到 2027 年的 174 億美元，複合年增長率為 18.5%。

在這份報告中，我們調查了全球蛋白質組學技術和市場、相關技術和發展的趨勢、影響市場增長的各種因素的分析、市場規模的趨勢和預測，以及分類/地區/主要國家。它總結了詳細的分析，競爭環境，主要公司概況等。

內容

第一章介紹

第 2 章要點摘要

第 3 章：概述

• 蛋白質組技術
• 報告範圍
• 蛋白質組學市場
• 蛋白質組學行業發展背後的驅動力
  • 司機
  • 約束因素
  • 機會
  • 任務
  • 蛋白質組學行業

第 4 章 COVID-19 對蛋白質組學市場的影響

• 概覽
• COVID-19 危機
• 對市場的影響
• 當前展望
  • 對癌症診斷的影響
  • COVID-19 影響的主要依據

第5章蛋白質組學技術

• 基於 MS 的蛋白質組學技術
  • 樣品製備分析
  • 標記/親和方法
  • 蛋白質組學在生物標誌物鑑定中的用途
  • MS 儀器和耗材
• 基於生物芯片的蛋白質組學技術
  • 多重蛋白質組學系統
  • 蛋白質組學
  • 蛋白質組學技術的最新進展

第 6 章蛋白質組學在藥物發現和開發中的應用

• 目標發現
• 潛在客戶識別
• 閱讀優化
• 臨床前研究

第 7 章蛋白質組學科學計劃

第 8 章蛋白質組學的臨床應用

• 應用於癌症
  • 概覽
  • 膀胱癌
  • 乳腺癌
  • 結腸癌
  • 胃癌
  • 腎癌
  • 肺癌
  • 淋巴瘤
  • 卵巢癌
  • 泛癌
  • 前列腺癌
  • 甲狀腺癌
  • 其他癌症
• 感染
• 糖尿病
• 神經系統疾病
  • 阿爾茨海默病
  • 精神分裂症
• 免疫疾病
  • HLA 分型
  • 自身免疫性疾病
• 心血管疾病
• 先兆子癇

第 9 章蛋白質組學行業

• 工業收購
• 行業戰略聯盟
• 質譜行業
• 色譜行業
• 基於蛋白質組學的藥物發現和開發行業
• 蛋白質組學生物芯片行業
  • 多□微陣列行業
  • 高密度蛋白陣列產業
• 抗體微陣列產業
• 中國生物芯片產業
• 芯片實驗室蛋白質組學行業
• 化學蛋白質組學行業
• 抗體試劑行業
• 多重蛋白質診斷行業
• 幹血點蛋白組學行業
• 單細胞蛋白質組學行業

第十章蛋白質組學市場

• 蛋白質組學行業發展背後的驅動力
• 全球蛋白質組學市場
• 市場概覽
• 研究市場
• 藥物發現和開發市場
• 蛋白質組學診斷市場
• 基於質譜的蛋白質組學市場
• 基於生物芯片的蛋白質組學市場

第 11 章蛋白質組學市場：按地區

• 北美
• 歐洲
• 亞太地區
• 其他地區

第12章蛋白質組學專利

• 美國蛋白質組學專利
• 蛋白質陣列專利

第13章競爭格局

• 基因組學和蛋白□□質組學工具/技術
  • 測序技術
  • PCR技術
  • 核酸純化和分離
  • 核酸分離技術

第14章公司簡介

• ABCODIA LTD.
• ACTIVX BIOSCIENCES INC.
• ADVANCED PROTEOME THERAPEUTICS INC.
• AGILENT TECHNOLOGIES INC.
• APPLIED PROTEOMICS
• ARRAYIT CORP.
• ASTUTE MEDICAL INC.
• AVACTA LIFE SCIENCES LTD.
• AYOXXA BIOSYSTEMS GMBH
• BECTON, DICKINSON AND CO.
• BIOCARTIS NV
• BIODESIX INC.
• BIOGNOSYS AG
• BIOMERIEUX SA
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE INC.
• BRUKER CORP.
• CAMBRIDGE PROTEIN ARRAYS LTD.
• CHARLES RIVER LABORATORIES INTERNATIONAL INC.
• CRYSTALGENOMICS INC.
• DANAHER CORP.
• EPICYPHER INC.
• EVOTEC AG
• GENERAL ELECTRIC CO.
• GLAXOSMITHKLINE PLC
• GL SCIENCES INC.
• ILLUMINA INC.
• IMMUNOVIA AB
• IMTAKT CORP.
• INTEGRATED DIAGNOSTICS HOLDING
• INDI MOLECULAR
• LABCYTE INC.
• LIMINAL BIOSCIENCES INC.
• MERCK & CO. INC.
• MERCK KGAA
• MRM PROTEOMICS INC.
• MYCARTIS
• MYRIAD GENETICS INC.
• NEWOMICS INC.
• NIRMIDAS BIOTECH INC.
• OLINK BIOSCIENCE
• OPKO HEALTH INC.
• PERKINELMER INC.
• PERSONALIZED CANCER THERAPY INC.
• PFIZER INC.
• PHENOMENEX INC.
• PRESSURE BIOSCIENCES INC.
• PROTAGEN AG
• PROTEA BIOSCIENCES INC.
• PROTEOCYTE DIAGNOSTICS INC.
• PROTEOGENIX
• PROTEOME SCIENCES PLC
• PROTEOMICS INTERNATIONAL PTY LTD.
• PYC THERAPEUTICS.（FORMERLY PHYLOGICA LTD.）
• QIAGEN N.V.
• QUANSYS BIOSCIENCES
• QUANTERIX INC.
• QUEST DIAGNOSTICS INC.
• REPLIGEN CORP.
• ROCHE（F. HOFFMANN-LA ROCHE LTD.）
• SAMDI TECH INC.
• SANOFI
• SERA PROGNOSTICS
• SHIMADZU CORP.
• SHISEIDO COMPANY LTD.
• SHOWA DENKO KK
• SINGULEX INC.
• SISCAPA ASSAY TECHNOLOGIES INC.
• SOMALOGIC INC.
• SPOTON CLINICAL DIAGNOSTICS LTD.
• SQI DIAGNOSTICS
• STANDARD BIOTOOLS INC.（FORMERLY FLUIDIGM）
• SYNAGEVA BIOPHARMA（ACQUIRED BY ALEXION PHARMACEUTICALS INC.）
• T2 BIOSYSTEMS
• THERMO FISHER SCIENTIFIC INC.
• THORNE DIAGNOSTICS INC.
• TOSOH CORP.
• TRAJAN SCIENTIFIC AND MEDICAL
• UNIVERSAL BIOSENSORS LTD.
• VG LIFE SCIENCES INC.
• WATERS CORP.
• XENCOR INC.
• YMC CO. LTD.

Highlights:

The global proteomics market should reach $55.1 billion by 2027 from $27.1 billion in 2022 at a compound annual growth rate (CAGR) of 15.3% for the forecast period of 2022 to 2027.

Drug discovery and development segment of the global proteomics market is expected to grow from $14.0 billion in 2022 to $26.1 billion in 2027 at a CAGR of 13.2% for the forecast period of 2022 to 2027.

Diagnostics segment of the global proteomics market is expected to grow from $7.4 billion in 2022 to $17.4 billion in 2027 at a CAGR of 18.5% for the forecast period of 2022 to 2027.

Report Scope:

The study's scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays, and LOACs. It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets-North America, Europe, Asia-Pacific, and Rest of the World (ROW)-are included.

The MS market is covered by instrument type, MS consumables, and product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth to 2027.

Technology status and forces driving the market are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs, and competitive trends.

Key industry acquisitions and strategic alliances are given for the five-year period from 2021 through 2027.

This report examines the main patent trends within the industry and profiles proteomics companies.

Report Includes:

• 149 data tables and 97 additional tables
• An up-to-date overview of the global markets for proteomics and related technologies
• Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Highlights of the upcoming market potential for the global proteomics industry, growth driving factors, and areas of focus to forecast this market into various segments and sub-segments
• Estimation of the actual market size and market forecast for proteomics in value (USD millions) terms, and their corresponding market share analysis by platform technology, end-user application, and region
• In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in proteomics, and COVID-19 impact on the market for proteomics
• Insight into recent industry structure for proteomics technologies, competitive aspects of each product segments, major growth strategies, and company value share analysis based on their segmental revenues
• Updated information on key mergers and acquisition deals, agreements, partnerships, collaborations and product launches within the global proteomics industry
• Profile descriptions of the leading proteomics manufacturers, including Agilent, Danaher Corp., GlaxoSmithKline PLC, PerkinElmer Inc., Qiagen GmbH, and Sanofi.

Table of Contents

Chapter 1 Introduction

• 1.1 Study Goals and Objectives
• 1.2 Reasons for Doing the Study
• 1.3 What's New in This Update?
• 1.4 Scope of Report
• 1.5 Intended Audience
• 1.6 Methodology
• 1.7 Information Sources
• 1.8 Analyst's Credentials
• 1.9 BCC Custom Research
• 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

• 3.1 Proteomic Technologies
• 3.2 Scope of Report
• 3.3 Proteomics Market
• 3.4 Driving Forces for Proteomics Industry Growth
  • 3.4.1 Drivers
  • 3.4.2 Restraints
  • 3.4.3 Opportunities
  • 3.4.4 Challenge
  • 3.4.5 Proteomics Industry

Chapter 4 COVID 19 Impact on Proteomics Market

• 4.1 Overview
• 4.2 COVID-19 Crisis
• 4.3 Impact on Market
• 4.4 Current Outlook
  • 4.4.1 Implications on Cancer Diagnosis
  • 4.4.2 Key Reasons for Impact of COVID-19

Chapter 5 Proteomics Technologies

• 5.1 Introduction
• 5.2 MS-Based Proteomics Technologies
  • 5.2.1 Sample Preparation Assays
  • 5.2.2 Tagging/Affinity Methods
  • 5.2.3 Utility of Proteomics to Identify Biomarkers
  • 5.2.4 MS Instruments and Consumables
• 5.3 Biochip-Based Proteomics Technologies
  • 5.3.1 Multiplex Proteomics Systems
  • 5.3.2 Proteogenomics
  • 5.3.3 Recent Advances in Proteomics Technologies

Chapter 6 Proteomics Applications in Drug Discovery and Development

• 6.1 Target Discovery
• 6.2 Lead Identification
• 6.3 Lead Optimization
• 6.4 Preclinical Studies

Chapter 7 Proteomics Scientific Initiatives

Chapter 8 Clinical Proteomics Applications

• 8.1 Applications in Cancer
  • 8.1.1 Overview
  • 8.1.2 Bladder Cancer
  • 8.1.3 Breast Cancer
  • 8.1.4 Colorectal Cancer
  • 8.1.5 Gastric Cancer
  • 8.1.6 Kidney Cancer
  • 8.1.7 Lung Cancer
  • 8.1.8 Lymphomas
  • 8.1.9 Ovarian Cancer
  • 8.1.10 Pan-Cancer
  • 8.1.11 Prostate Cancer
  • 8.1.12 Thyroid Cancer
  • 8.1.13 Other Cancers
• 8.2 Infectious Diseases
• 8.3 Diabetes
• 8.4 Neurological Disorders
  • 8.4.1 Alzheimer's Disease
  • 8.4.2 Schizophrenia
• 8.5 Immune Diseases
  • 8.5.1 HLA Typing
  • 8.5.2 Autoimmune Disease
• 8.6 Cardiovascular Disease
• 8.7 Preeclampsia

Chapter 9 Proteomics Industry

• 9.1 Industry Acquisitions
• 9.2 Industry Strategic Alliances
• 9.3 Mass Spectrometry Industry
• 9.4 Chromatography Industry
• 9.5 Proteomics-Based Drug Discovery and Development Industry
• 9.6 Proteomics Biochip Industries
  • 9.6.1 Peptide Microarray Industry
  • 9.6.2 High-Density Protein Array Industry
• 9.7 Antibody Microarray Industry
• 9.8 China's Biochip Industry
• 9.9 Lab-on-a-Chip Proteomics Industry
• 9.10 Chemical Proteomics Industry
• 9.11 Antibody Reagent Industry
• 9.12 Multiplex Protein Diagnostics Industry
• 9.13 Dried Blood Spotting Proteomics Industry
• 9.14 Single Cell Proteomics Industry

Chapter 10 Proteomics Markets

• 10.1 Driving Forces of Proteomics Industry Growth
• 10.2 Global Proteomics Markets
• 10.3 Market Summary
• 10.4 Research Market
• 10.5 Drug Discovery and Development Market
• 10.6 Proteomics Diagnostic Market
• 10.7 Mass Spectrometry-Based Proteomics Market
• 10.8 Biochip-Based Proteomics Market

Chapter 11 Proteomics Market by Geographic Segmentation

• 11.1 North America
  • 11.1.1 United States
  • 11.1.1 Canada
• 11.2 Europe
  • 11.2.1 Impact of Brexit
  • 11.2.2 United Kingdom
  • 11.2.3 Germany
  • 11.2.4 France
  • 11.2.5 Italy
  • 11.2.6 Spain
  • 11.2.7 Rest of Europe
• 11.3 Asia-Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Rest of Asia-Pacific
• 11.4 Rest of the World (RoW)

Chapter 12 Proteomics Patents

• 12.1 U.S. Proteomics Patents
• 12.2 Protein Array Patents
  • 12.2.1 Lab-on-a-Chip Patents
  • 12.2.2 Mass Spectrometry Patents

Chapter 13 Competitive Landscape

• 13.1 Genomics and Proteomic Tools/Technologies
  • 13.1.1 Sequencing Technologies
  • 13.1.2 PCR Technology
  • 13.1.3 Nucleic Acid Purification and Separation
  • 13.1.4 Nucleic Acid Separation Technologies

Chapter 14 Company Profiles

• ABCODIA LTD.
• ACTIVX BIOSCIENCES INC.
• ADVANCED PROTEOME THERAPEUTICS INC.
• AGILENT TECHNOLOGIES INC.
• APPLIED PROTEOMICS
• ARRAYIT CORP.
• ASTUTE MEDICAL INC.
• AVACTA LIFE SCIENCES LTD.
• AYOXXA BIOSYSTEMS GMBH
• BECTON, DICKINSON AND CO.
• BIOCARTIS NV
• BIODESIX INC.
• BIOGNOSYS AG
• BIOMERIEUX SA
• BIO-RAD LABORATORIES INC.
• BIO-TECHNE INC.
• BRUKER CORP.
• CAMBRIDGE PROTEIN ARRAYS LTD.
• CHARLES RIVER LABORATORIES INTERNATIONAL INC.
• CRYSTALGENOMICS INC.
• DANAHER CORP.
• EPICYPHER INC.
• EVOTEC AG
• GENERAL ELECTRIC CO.
• GLAXOSMITHKLINE PLC
• GL SCIENCES INC.
• ILLUMINA INC.
• IMMUNOVIA AB
• IMTAKT CORP.
• INTEGRATED DIAGNOSTICS HOLDING
• INDI MOLECULAR
• LABCYTE INC.
• LIMINAL BIOSCIENCES INC.
• MERCK & CO. INC.
• MERCK KGAA
• MRM PROTEOMICS INC.
• MYCARTIS
• MYRIAD GENETICS INC.
• NEWOMICS INC.
• NIRMIDAS BIOTECH INC.
• OLINK BIOSCIENCE
• OPKO HEALTH INC.
• PERKINELMER INC.
• PERSONALIZED CANCER THERAPY INC.
• PFIZER INC.
• PHENOMENEX INC.
• PRESSURE BIOSCIENCES INC.
• PROTAGEN AG
• PROTEA BIOSCIENCES INC.
• PROTEOCYTE DIAGNOSTICS INC.
• PROTEOGENIX
• PROTEOME SCIENCES PLC
• PROTEOMICS INTERNATIONAL PTY LTD.
• PYC THERAPEUTICS. (FORMERLY PHYLOGICA LTD.)
• QIAGEN N.V.
• QUANSYS BIOSCIENCES
• QUANTERIX INC.
• QUEST DIAGNOSTICS INC.
• REPLIGEN CORP.
• ROCHE (F. HOFFMANN-LA ROCHE LTD.)
• SAMDI TECH INC.
• SANOFI
• SERA PROGNOSTICS
• SHIMADZU CORP.
• SHISEIDO COMPANY LTD.
• SHOWA DENKO KK
• SINGULEX INC.
• SISCAPA ASSAY TECHNOLOGIES INC.
• SOMALOGIC INC.
• SPOTON CLINICAL DIAGNOSTICS LTD.
• SQI DIAGNOSTICS
• STANDARD BIOTOOLS INC. (FORMERLY FLUIDIGM)
• SYNAGEVA BIOPHARMA (ACQUIRED BY ALEXION PHARMACEUTICALS INC.)
• T2 BIOSYSTEMS
• THERMO FISHER SCIENTIFIC INC.
• THORNE DIAGNOSTICS INC.
• TOSOH CORP.
• TRAJAN SCIENTIFIC AND MEDICAL
• UNIVERSAL BIOSENSORS LTD.
• VG LIFE SCIENCES INC.
• WATERS CORP.
• XENCOR INC.
• YMC CO. LTD.

List of Tables

• Summary Table A : Global Proteomics Market, by End-User Industry, Through 2027
• Summary Table B : Global Proteomics Market, by Platform, Through 2027
• Table 1 : Global Array Versus Lab-on-a-Chip (LOC) Biochips
• Table 2 : Scope of Report
• Table 3 : Global Proteomics Market, by Platform, Through 2027
• Table 4 : Global Biochips Market, by Type, Through 2027
• Table 5 : Driving Forces in the Growth of the Proteomics Industry
• Table 6 : Biochip Industry Comparisons
• Table 7 : Mass Spectrometry Generalized Workflow Schematic
• Table 8 : Mass Spectrometer Platforms
• Table 9 : Biochip-Based Proteomics Technologies
• Table 10 : Planar-Based Versus Bead-Based Arrays
• Table 11 : Advantages of Multiplexing for Diagnostics
• Table 12 : Technical Advances in Proteomics
• Table 13 : Proteomic Applications in Drug Discovery and Development
• Table 14 : Large-Scale Proteomics Initiatives
• Table 15 : Some Cancer Markers Used in Diagnosis and Treatment
• Table 16 : Strategies for Overcoming High-Abundance Proteins in Clinical Samples
• Table 17 : Status of Next-Generation Diagnostic Tests for Bladder Cancer
• Table 18 : Number of Annual Breast Cancer Treatment Decisions in the U.S, by Cancer Classification
• Table 19 : Breast Cancer MDx Technology Platforms
• Table 20 : Status of Next-Generation Tests for Breast Cancer
• Table 21 : Status of Next-Generation Diagnostic Tests for Gastric/Stomach Cancer
• Table 22 : Status of Next-Generation Diagnostic Tests for Kidney Cancer
• Table 23 : Status of Next-Generation Diagnostic Tests for Lung Cancer
• Table 24 : Status of Next-Generation Diagnostic Tests for Lymphomas
• Table 25 : Early Screening Tests for Ovarian Cancer
• Table 26 : Status of Next-Generation Diagnostics Tests for Ovarian Cancer
• Table 27 : Status of Next-Generation Diagnostics Tests for Pan-Cancer
• Table 28 : Status of Next-Generation Diagnostics Tests for Prostate Cancer
• Table 29 : Status of Next-Generation Diagnostics Tests for Thyroid Cancer
• Table 30 : Alzheimer's Disease Diagnostic Approaches
• Table 31 : Multiplex Autoimmune Testing Market
• Table 32 : Preeclampsia Diagnostic Tests
• Table 33 : Proteomics Industry Acquisitions, 2017-2022
• Table 34 : Strategic Alliances in the Proteomics Industry
• Table 35 : Mass Spectrometry Industry: Porter's Five Forces Analysis
• Table 36 : First-Tier Mass Spectrometry Companies
• Table 37 : Second-Tier Mass Spectrometry Companies
• Table 38 : Leading Manufacturers of High-Performance Liquid Chromatography Columns
• Table 39 : Leading Manufacturers of High-Performance Liquid Chromatography Columns in Japan
• Table 40 : Proteomics-Based Drug Discovery Industry
• Table 41 : Key Peptide Microarray Companies
• Table 42 : Leading High-Density Protein Array Companies
• Table 43 : Key Antibody Microarray Companies
• Table 44 : Leading Companies in China's Biochip Industry
• Table 45 : Lab-on-a-Chip Competitor Landscape
• Table 46 : Antibody Reagent Market Share, by Company, 2021
• Table 47 : Multiplex Protein In Vitro Diagnostics Companies
• Table 48 : Dried Blood Spot Proteomics Industry
• Table 49 : Single Cell Proteomics Industry
• Table 50 : Factors Driving the Growth of the Proteomics Industry
• Table 51 : Global Proteomic Market, by End-User Industry, Through 2027
• Table 52 : Global Proteomics Research Market, by Platform, Through 2027
• Table 53 : Global Proteomics Research Market, by Biochip Platform, Through 2027
• Table 54 : Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
• Table 55 : Global Proteomics Biochip Drug Discovery and Development Market, by Biochip Platform, Through 2027
• Table 56 : Global Proteomics Diagnostic Market, by Platform, Through 2027
• Table 57 : Global Proteomics Diagnostic Market, by Biochip Type, Through 2027
• Table 58 : Global Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 59 : Status of Proteomics-Based Diagnostics for Diabetes, Neurological, Autoimmune, Infectious Disease, HLA Typing, and Cardiovascular Disease Applications
• Table 60 : Sepsis Diagnostics Industry
• Table 61 : Global Proteomics Cancer Diagnostic Market, by Indication, Through 2027
• Table 62 : Global Mass Spectrometry Market, by Product Type, Through 2027
• Table 63 : Global Mass Spectrometry Market, by End-User Industry, Through 2027
• Table 64 : MRM-MS versus MALDI MS in Clinical Applications
• Table 65 : Status of MS Clinical Test Platforms
• Table 66 : Phosphoproteomics Platforms for Cancer Applications
• Table 67 : Global Proteomics Biochip Market, by Type, Through 2027
• Table 68 : Global Proteomics Arrays Market, by Type, Through 2027
• Table 69 : Global Proteomics Market, by End-User Industry, Through 2027
• Table 70 : Global Proteomics Drug Discovery and Development Market, by Platform, Through 2027
• Table 71 : Global Proteomics Lab-on-a-Chip Market, by End-User Industry, Through 2027
• Table 72 : Global Proteomics Market, by Region, Through 2027
• Table 73 : Global Proteomic Diagnostic Market, by Region, Through 2027
• Table 74 : North American Proteomics Market by Country, Through 2027
• Table 75 : North American Proteomics Market, by Platform, Through 2027
• Table 76 : North American Proteomics Market, by Biochips Platform, Through 2027
• Table 77 : North American Proteomics Market, by End User, Through 2027
• Table 78 : North American Drug Discovery and Development Market, by Platform, Through 2027
• Table 79 : North American Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 80 : North American Proteomics Research Market, by Platform, Through 2027
• Table 81 : U.S. Proteomics Market, by Platform, Through 2027
• Table 82 : U.S. Proteomics Market, by Biochips Platform, Through 2027
• Table 83 : U.S. Proteomics Market, by End User, Through 2027
• Table 84 : U.S. Drug Discovery and Development Market, by Platform, Through 2027
• Table 85 : U.S. Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 86 : U.S. Proteomics Research Market, by Platform, Through 2027
• Table 87 : Canadian Proteomics Market, by Platform, Through 2027
• Table 88 : Canadian Proteomics Market, by Biochips Platform, Through 2027
• Table 89 : Canadian Proteomics Market, by End User, Through 2027
• Table 90 : Canadian Drug Discovery and Development Market, by Platform, Through 2027
• Table 91 : Canadian Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 92 : Canadian Proteomics Research Market, by Platform, Through 2027
• Table 93 : European Proteomics Market, by Country, Through 2027
• Table 94 : European Proteomics Market, by Platform, Through 2027
• Table 95 : European Proteomics Market, by Biochips Platform, Through 2027
• Table 96 : European Proteomics Market, by End User, Through 2027
• Table 97 : European Drug Discovery and Development Market, by Platform, Through 2027
• Table 98 : European Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 99 : European Proteomics Research Market, by Platform, Through 2027
• Table 100 : U.K. Proteomics Market, by Platform, Through 2027
• Table 101 : U.K. Proteomics Market, by Biochips Platform, Through 2027
• Table 102 : U.K. Proteomics Market, by End User, Through 2027
• Table 103 : U.K. Drug Discovery and Development Market, by Platform, Through 2027
• Table 104 : U.K. Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 105 : U.K. Proteomics Research Market, by Platform, Through 2027
• Table 106 : German Proteomics Market, by Platform, Through 2027
• Table 107 : German Proteomics Market, by Biochips Platform, Through 2027
• Table 108 : German Proteomics Market, by End User, Through 2027
• Table 109 : German Drug Discovery and Development Market, by Platform, Through 2027
• Table 110 : German Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 111 : German Proteomics Research Market, by Platform, Through 2027
• Table 112 : French Proteomics Market, by Platform, Through 2027
• Table 113 : French Proteomics Market, by Biochips Platform, Through 2027
• Table 114 : French Proteomics Market, by End User, Through 2027
• Table 115 : French Drug Discovery and Development Market, by Platform, Through 2027
• Table 116 : French Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 117 : French Proteomics Research Market, by Platform, Through 2027
• Table 118 : Italian Proteomics Market, by Platform, Through 2027
• Table 119 : Italian Proteomics Market, by Biochips Platform, Through 2027
• Table 120 : Italian Proteomics Market, by End User, Through 2027
• Table 121 : Italian Drug Discovery and Development Market, by Platform, Through 2027
• Table 122 : Italian Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 123 : Italian Proteomics Research Market, by Platform, Through 2027
• Table 124 : Spanish Proteomics Market, by Platform, Through 2027
• Table 125 : Spanish Proteomics Market, by Biochips Platform, Through 2027
• Table 126 : Spanish Proteomics Market, by End User, Through 2027
• Table 127 : Spanish Drug Discovery and Development Market, by Platform, Through 2027
• Table 128 : Spanish Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 129 : Spanish Proteomics Research Market, by Platform, Through 2027
• Table 130 : Rest of European Proteomics Market, by Platform, Through 2027
• Table 131 : Rest of European Proteomics Market, by Biochips Platform, Through 2027
• Table 132 : Rest of European Proteomics Market, by End User, Through 2027
• Table 133 : Rest of European Drug Discovery and Development Market, by Platform, Through 2027
• Table 134 : Rest of European Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 135 : Rest of European Proteomics Research Market, by Platform, Through 2027
• Table 136 : Asia-Pacific Proteomics Market, by Country, Through 2027
• Table 137 : Asia-Pacific Proteomics Market, by Platform, Through 2027
• Table 138 : Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
• Table 139 : Asia-Pacific Proteomics Market, by End User, Through 2027
• Table 140 : Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
• Table 141 : Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 142 : Asia-Pacific Proteomics Research Market, by Platform, Through 2027
• Table 143 : Chinese Proteomics Market, by Platform, Through 2027
• Table 144 : Chinese Proteomics Market, by Biochips Platform, Through 2027
• Table 145 : Chinese Proteomics Market, by End User, Through 2027
• Table 146 : Chinese Drug Discovery and Development Market, by Platform, Through 2027
• Table 147 : Chinese Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 148 : Chinese Proteomics Research Market, by Platform, Through 2027
• Table 149 : Japanese Proteomics Market, by Platform, Through 2027
• Table 150 : Japanese Proteomics Market, by Biochips Platform, Through 2027
• Table 151 : Japanese Proteomics Market, by End User, Through 2027
• Table 152 : Japanese Drug Discovery and Development Market, by Platform, Through 2027
• Table 153 : Japanese Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 154 : Japanese Proteomics Research Market, by Platform, Through 2027
• Table 155 : Indian Proteomics Market, by Platform, Through 2027
• Table 156 : Indian Proteomics Market, by Biochips Platform, Through 2027
• Table 157 : Indian Proteomics Market, by End User, Through 2027
• Table 158 : Indian Drug Discovery and Development Market, by Platform, Through 2027
• Table 159 : Indian Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 160 : Indian Proteomics Research Market, by Platform, Through 2027
• Table 161 : South Korean Proteomics Market, by Platform, Through 2027
• Table 162 : South Korean Proteomics Market, by Biochips Platform, Through 2027
• Table 163 : South Korean Proteomics Market, by End User, Through 2027
• Table 164 : South Korean Drug Discovery and Development Market, by Platform, Through 2027
• Table 165 : South Korean Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 166 : South Korean Proteomics Research Market, by Platform, Through 2027
• Table 167 : Australian Proteomics Market, by Platform, Through 2027
• Table 168 : Australian Proteomics Market, by Biochips Platform, Through 2027
• Table 169 : Australian Proteomics Market, by End User, Through 2027
• Table 170 : Australian Drug Discovery and Development Market, by Platform, Through 2027
• Table 171 : Australian Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 172 : Australian Proteomics Research Market, by Platform, Through 2027
• Table 173 : Rest of Asia-Pacific Proteomics Market, by Platform, Through 2027
• Table 174 : Rest of Asia-Pacific Proteomics Market, by Biochips Platform, Through 2027
• Table 175 : Rest of Asia-Pacific Proteomics Market, by End User, Through 2027
• Table 176 : Rest of Asia-Pacific Drug Discovery and Development Market, by Platform, Through 2027
• Table 177 : Rest of Asia-Pacific Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 178 : Rest of Asia-Pacific Proteomics Research Market, by Platform, Through 2027
• Table 179 : Rest of the World Proteomics Market, by Platform, Through 2027
• Table 180 : Rest of the World Proteomics Market, by Biochips Platform, Through 2027
• Table 181 : Rest of the World Proteomics Market, by End User, Through 2027
• Table 182 : Rest of the World Drug Discovery and Development Market, by Platform, Through 2027
• Table 183 : Rest of the World Proteomics Diagnostic Market, by Disease Type, Through 2027
• Table 184 : Rest of the World Proteomics Research Market, by Platform, Through 2027
• Table 185 : U.S. Proteomics Patents, 2017-2022
• Table 186 : Europe: Proteomics Patents, 2017-2022
• Table 187 : Japan: Proteomics Patents, 2017-2022
• Table 188 : Array-related Proteomics Patents, by Region, 2017-2022
• Table 189 : LOC-Related Proteomics Patents, by Region, 2017-2022
• Table 190 : Mass Spectrometry-Related Proteomics Patents, by Region, 2017-2022
• Table 191 : Major Mergers, Acquisitions, Collaborations, Partnership, Spin-Offs and Agreements
• Table 192 : FDA Clearances, Patents and Approvals, 2017-2022
• Table 193 : New Product Launches, 2017-2022
• Table 194 : Key Products of Sequencing and Next-Generation Sequencing Tools and Reagents and Their Manufacturers in Asia-Pacific
• Table 195 : Top Manufacturers of PCR Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
• Table 196 : Key Products of PCR Tools and Reagents and Their Manufacturers in Asia-Pacific
• Table 197 : Top Manufacturers of Nucleic Acid Purification and Extraction Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
• Table 198 : Key Products of Nucleic Acid Purification and Extraction Tools and Reagents and Their Manufacturers in Asia-Pacific
• Table 199 : Top Manufacturers of Nucleic Acid Separation Technologies for Emerging Markets of Asia-Pacific for Research and Clinical Diagnostics
• Table 200 : Nucleic Acid Separation Technologies: Key Manufacturers' Product Portfolio
• Table 201 : Agilent: Laboratory Automation Systems and Processes Portfolio
• Table 202 : Agilent Technologies Inc.: Developments
• Table 203 : BD: Laboratory Automation Systems and Processes Portfolio
• Table 204 : BioMerieux: FDA Bacteriology Products Approved in 2020
• Table 205 : BioMerieux: Key Developments, 2021
• Table 206 : Bio-Rad: Key Developments, 2021
• Table 207 : Danaher Corp.: Key Developments
• Table 208 : GE Healthcare: Product Portfolio
• Table 209 : General Electric: Financials, 2019
• Table 210 : GE Healthcare: Product Portfolio
• Table 211 : GE Healthcare: Recent Developments
• Table 212 : GlaxoSmithKline PLC: Product Segment
• Table 213 : GlaxoSmithKline PLC: Key Financials, 2021
• Table 214 : GlaxoSmithKline PLC: Vaccines Offered
• Table 215 : GlaxoSmithKline PLC: Flu Vaccines Sales
• Table 216 : GlaxoSmithKline PLC: Recent Developments
• Table 217 : Illumina Inc.: Revenues and R&D Expenditures
• Table 218 : Illumina Inc.: Key Developments
• Table 219 : PerkinElmer Inc.: Revenues and R&D Expenditures
• Table 220 : PerkinElmer Inc.: Laboratory Automation Systems and Processes Portfolio
• Table 221 : PerkinElmer Inc.: Selected Recent Developments
• Table 222 : Pressure BioSciences Inc.: Revenues and R&D Expenditures
• Table 223 : Pressure BioSciences Inc.: Key Developments
• Table 224 : Qiagen GmbH: Laboratory Automation Systems and Processes Portfolio
• Table 225 : Qiagen GmbH: Developments
• Table 226 : Roche: Business Segment
• Table 227 : Roche: Financials, 2021
• Table 228 : Roche: Financial Performance, 2018-2020
• Table 229 : Roche: Product Portfolio
• Table 230 : Roche: Diagnostics Patient Monitoring Product Portfolio
• Table 231 : Roche: Oncology Pharmaceutical Product Portfolio
• Table 232 : Roche: Oncology Pharmaceutical Revenue, 2018-2020
• Table 233 : Roche: Recent Developments
• Table 234 : Sanofi: Business Segment
• Table 235 : Sanofi: Financial Performance, 2021
• Table 236 : Sanofi-Aventis: Oncology Pharmaceuticals Product Portfolio
• Table 237 : Sanofi-Aventis: Oncology Pharmaceuticals Revenue, 2018-2020
• Table 238 : Somalogic: Proteomics Methods
• Table 239 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 240 : Thermo Fisher Scientific Inc.: Developments
• Table 241 : Universal Biosensors Diagnostic Pipeline
• Table 242 : Waters Corp.: Revenues and R&D Expenditures
• Table 243 : Waters Corp.: Laboratory Automation Systems and Processes Portfolio
• Table 244 : Waters Corp.: Key Developments

List of Figures

• Summary Figure A : Global Proteomics Market, by End-User Industry, 2019-2027
• Summary Figure B : Global Proteomics Market, by Platform, 2022-2027
• Figure 1 : Proteomics Biochip and Array Formats
• Figure 2 : Chromatography Proteomics Workflow
• Figure 3 : Agilent: Annual Revenue, Life Sciences and Applied Markets Segment, 2019-2021
• Figure 4 : Agilent: Revenue Share, by Region, Life Sciences and Applied Markets Segment, 2021
• Figure 5 : Danaher Corp.: Revenue Share, by Segment, 2020
• Figure 6 : Danaher: Life Sciences Segment, Annual Revenue, 2019-2021
• Figure 7 : Danaher: Life Sciences Segment Revenue Share, by Region, 2021
• Figure 8 : General Electric Co.: Revenue Share, by Complementary Segment, 2020
• Figure 9 : General Electric Co.: Revenue Share, by Region/Country, 2020
• Figure 10 : GE Healthcare: Revenue Share, by Region, 2019
• Figure 11 : GE Healthcare: Revenue Share, by Segment, 2019
• Figure 12 : GlaxoSmithKline PLC: Net Revenue, 2016-2021
• Figure 13 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2021
• Figure 14 : GlaxoSmithKline PLC: Revenue Share, by Region, 2021
• Figure 15 : Merck KGaA: Revenue Share, by Complementary Segment, 2020
• Figure 16 : Merck KGaA: Annual Revenue, 2017-2020
• Figure 17 : Merck KGaA: Revenue Share, by Region, 2020
• Figure 18 : Merck KGaA: Revenue Share, by Investment, 2020
• Figure 19 : Merck KGaA: Revenue Share, by Region, 2020
• Figure 20 : PerkinElmer Inc.: Annual Revenue, 2019-2021
• Figure 21 : PerkinElmer Inc.: Revenue Share, by Region, 2021
• Figure 22 : Qiagen: Annual Revenue, 2019-2021
• Figure 23 : Qiagen: Revenue Share, by Product Groups, 2021
• Figure 24 : Qiagen: Revenue Share, by Region, 2021
• Figure 25 : Roche: Revenue Share, by Segment, 2021
• Figure 26 : Roche: Total Sales Share, by Product Segment, 2020
• Figure 27 : Roche: Annual Revenue, 2019-2021
• Figure 28 : Roche Core Laboratory Diagnostics Segment: Annual Revenue, 2019-2021
• Figure 29 : Roche: Oncology Annual Revenue, 2018-2020
• Figure 30 : Sanofi: Net Sales Share, by Business Segment, 2021
• Figure 31 : Sanofi: Net Sales Share, by Region, 2021
• Figure 32 : Sanofi Oncology Pharmaceuticals: Annual Revenue, 2018-2020
• Figure 33 : Thermo Fisher Scientific Inc.: Revenue Share, by Segment, 2020
• Figure 34 : Thermo Fisher Scientific: Annual Revenue, 2019-2021
• Figure 35 : Thermo Fisher Scientific: Revenue Share, by Region, 2021
• Figure 36 : Waters Corp.: Annual Revenue, 2019-2021
• Figure 37 : Waters Corp.: Revenue Share, by Region, 2021